Patent Grant
11083796
The present invention relates to methods for reducing peroxide levels in non-polymeric preparations and to compositions used in and prepared by such methods.
Sucrose acetate isobutyrate (“SAIB”) is a hydrophobic liquid with limited water solubility. It is soluble in a large number of biocompatible solvents. SAIB has an unusual property—it undergoes a dramatic change in viscosity with small additions of heat or with the addition of solvents. It is a very viscous liquid, having a viscosity of approximately 3200 poise at 37° C. SAIB is produced by the controlled esterification of natural sugar (sucrose) with acetic and isobutyric anhydrides. SAIB metabolizes to sucrose, acetic acid and isobutyric acid.
SAIB is orally non-toxic and is currently used to stabilize emulsions in the food industry. In one example, SAIB is commonly found in the beverage industry, where it is used as a weighting agent to help stabilize the final beverage formula. Also, SAIB has been reported to be useful as a gelling system-type drug excipient that allows for sustained or controlled release of drugs. When in solution or in an emulsion, SAIB can be applied via injection or an aerosol spray. SAIB is compatible with cellulose esters and other polymers that can affect the rate of delivery of the substance. In one example, SAIB is the main ingredient for the SABER drug delivery system, which also consists of a pharmaceutically acceptable solvent.
Drug delivery systems, including SAIB delivery systems, are still confronted by various issues of drug instability, as such systems are considered for longer and longer drug delivery durations. Drug instability can occur via a number of factors, including denaturation, precipitation, oxidation, aggregation, and others. In particular, a number of excipients used to facilitate delivery and release of drugs have peroxides or are susceptible to the formation of peroxides, which may lead to oxidation of active ingredient in the formulation. In the example of SAIB, the presence of peroxides is deleterious to a drug incorporated in an SAIB drug formulation as the drug is likely to undergo oxidative degradation. Thus, in order to formulate any drug formulation based on SAIB that provides enough of a stable environment to facilitate the delivery of a drug, the peroxide levels must be reduced.
There is no known process for removal of peroxides from SAIB at present, despite availability of processes for the removal of peroxides from other materials such as polymers. Therefore, there still remains a need for a drug formulation of SAIB having improved properties to reduce the degradation of the drug therein.
An aspect of the present invention comprises methods of treating sucrose acetate isobutyrate (SAIB) formulations to be used as drug delivery vehicles comprising adding to the formulations an amount of bisulfite salt effective to substantially remove peroxides, the bisulfite salt comprising sodium metabisulfite, potassium metabisulfite, sodium bisulfite, or potassium bisulfite, or a mixture thereof.
In another aspect of the present invention, provided are drug delivery vehicles adapted to provide prolonged stability of a drug that is to be delivered in vivo comprising sucrose acetate isobutyrate having substantially reduced levels of peroxide, the drug delivery vehicle being treated with an amount of bisulfite salt effective to substantially reduce levels of peroxide in said drug delivery vehicle, the bisulfite salt comprising sodium metabisulfite, potassium metabisulfite, sodium bisulfite, or potassium bisulfite, or a combination thereof.
The invention is illustrated by way of example and is not intended to be limited by the accompanying figures.
In an aspect of the present invention, provided are methods of treating sucrose acetate isobutyrate formulations (SAID) that are to be used as drug delivery vehicles comprising adding an amount of a bisulfite salt effective for substantially removing peroxide from the formulations, the bisulfite salt comprising sodium metabisulfite, potassium metabisulfite, sodium bisulfite, or potassium bisulfite, or a combination thereof. Preferably, the bisulfite salt is sodium metabisulfite. A ratio ranging from about 1:1 to about 1:4 (weight:volume) SAIB:aqueous solution of bisulfite salt (“aqueous bisulfite salt”) can be used. Preferably, the bisulfite salt is a metabisulfite salt. In some embodiments, the bisulfite salt is preferably sodium metabisulfite. Preferably, the ratio of the aqueous bisulfite salt to SAIB is 1:1. In one example, to purify 1 kg of SAID, a volume of sodium metabisulfite solution can be made up to 1 liter, and an approximate proportion of 1:1 of SAIB:aqueous sodium metabisulfite was used. The aqueous bisulfite salt in SAID can be from about 0.1% weight to volume of water (w/v) to about 50% w/v; preferably, from about 0.5% w/v to about 30% w/v. In some embodiments, the aqueous bisulfite salt is preferably from about 1% w/v to about 15% w/v. In some embodiments, the aqueous bisulfite salt is about 5% w/v solution in water.
The method removes peroxide to a level that is at least less than 50% of the levels before the method, or starting levels, and, preferably, less than 20% of the starting levels. In some embodiments, peroxide is removed to less than 10% of the starting levels. While in some embodiments, the method removes peroxide to a level that is less than 5% of the starting levels. Furthermore, the method can remove peroxide so that the resulting SAIB formulation contains peroxide in amounts less than 20 ppm, and, preferably, less than 10 ppm. In some embodiments, the method removes peroxide to result in an SAIB formulation containing less than 5 ppm. In some embodiments, the resulting SAIB formulation from this method can serve as a drug delivery vehicle for use with a medical delivery device, including a drug eluting stent, a catheter, or other drug delivery implants. In one example, the SAIB formulation can be loaded into an osmotically pump-driven implantable device of the type disclosed in U.S. Pat. No. 6,395,292, for example. Preferably, the osmotically pump-driven implantable device is a Duros® device (Alza Corporation, Mountain View, Calif.). In other embodiments, the SAIB formulation can serve as a drug depot for drug delivery.
In some embodiments, the step of adding the bisulfite salt comprises mixing a solution of the bisulfite salt with the sucrose acetate isobutyrate formulation. The SAIB formulation can be further comprised of a cosolvent, which can be selected from a number of solvents including pharmaceutically acceptable solvents, e.g., hexane, ethyl acetate, ethanol, benzyl benzoate, N-methyl pyrrolidone, and iso-propyl alcohol, among others. Preferably, the cosolvent is hexane or ethyl acetate. In some embodiments, the methods further comprise vacuum treating the formulation to remove the cosolvent. Also, some embodiments comprise the additional step of removing bisulfite salt from the formulation. This removal step comprises washing the formulation with water to remove the bisulfite salt. In the embodiments that incorporate the washing step, a further step of drying the formulation over magnesium sulfate can be utilized to remove the water. Alternatively, calcium chloride anhydrous, calcium sulfate anhydrous, activated silica gel, phosphorous pentoxide, or drying under vacuum, or a combination thereof can be used to also remove the water. In alternative embodiments, glycerin can be used to wash the bisulfite-added formulation to remove the bisulfite salt. Afterwards, residual glycerin can be removed by washing with water and then drying to remove water.
In some aspects of the present invention, the methods of substantially removing peroxide from a sucrose acetate isobutyrate formulation (SAW) comprising the steps of adding the aqueous bisulfite salt, washing the formulation, and drying the formulation are repeated at least once. The steps can be repeated to further reduce the levels of peroxide in the SAIB formulation.
In another aspect, the present invention includes a drug delivery vehicle comprising SAW that provides for prolonged stability of a drug that is to be delivered by maintaining substantially reduced levels of peroxide, the drug delivery vehicle being treated with sodium metabisulfite. The prolonged stability comprises reduced oxidation, deamidation, or aggregation, e.g., dimerization, of the drug over extended periods of time in which drug is within environment of delivery vehicle. Preferably the prolonged stability is reduced oxidation. The extended periods of time can be periods from about one week to a few months, and up to about a year. Preferably, the prolonged stability is evidenced by significant improvements in oxidation, deamidation, or aggregation levels of the drug when the delivery vehicle has been treated with a bisulfite salt versus untreated delivery vehicle. In some preferred embodiments, the prolonged stability is characterized as about 50% less oxidation, about 33% less deamidation, or about 75% less dimerization as compared to untreated delivery vehicles. The drug can be selected from any known and desired biomolecular material that can act as therapeutics and other therapeutic active agents that are susceptible to oxidative degradation. As it is used herein, the term “biomolecular material” refers to peptides, polypeptides, proteins, nucleic acids, viruses, antibodies, small molecules susceptible to oxidation, and any other naturally derived, synthetically produced, or recombinantly produced active agent that includes nucleic or amino acid. In some embodiments, for example, drugs can be selected from among the following: a steroid, MAIDS, peptides, proteins such as growth factors or hormones, anti-tumor agents, antibiotics, analgesics, local anesthetics, antiviral agents, antipsychotics, anticoagulants, oligonucleotides for gene therapy, active small molecules, and others.
As used herein, the term “removing” and all variations thereof, refer to decreasing by any measurable degree the level of peroxide present in a drug formulation. The term “substantially removing” is used herein to describe a dramatic decrease in the level of peroxide present in a drug formulation, such as SAW formulation. The dramatic decrease is at least 50% of original levels (levels before treatment) and in some instances is 10% of original levels. In preferred aspects of the present invention, the “substantial removal” describes a decrease to less than 5% of original levels.
As used herein, the term “drug delivery vehicle” or “delivery vehicle” refers to a formulation that is biocompatible and used to carry a drug without reacting with the same drug. Also, the vehicle does not alter or minimally alters the activity of the drug. Furthermore, the vehicle allows for the transport of the drug in vivo and eventual delivery of the drug to a biological site for therapeutic effect.
As used herein, the term “prolonged stability” is used to refer to the stabilizing effect of the drug delivery vehicles of the present invention on the carried drug. Prolonged stability can be evidenced by significant improvements in oxidation, deamidation, or aggregation of the drug over extended periods of time.
Different approaches were investigated for removal of peroxides from SA113, as indicated in Table 1.
Preparation of Suspension
Each of the experiments involved protein particles consisting of omega-interferon, which were suspended in SAIB at a particle loading of either 4% or 10% by weight. The suspensions were prepared in a dry box under nitrogen at 45° C. The suspension was mixed for 15 minutes while maintaining the temperature. Suspension mixing was performed by hand. Aliquots from the prepared suspensions were transferred to clear crimp-top glass vials and sealed under nitrogen. Each aliquot contained at least six milligrams of protein to allow for stability testing in triplicate. These samples were stored in an oven at 40° C. Samples were withdrawn at regular intervals (as indicated in Table 1) and analyzed for omega-interferon content and purity was assessed using reverse phase I-IPLC and size exclusion chromatography.
Size Exclusion Chromatography
Size exclusion chromatography (SEC) was used to monitor the omega-interferon content and purity in the formulations. The percentages of monomer and dimer in the formulation were quantified using SEC. The stability of omega-interferon was judged by using a stability indicating chromatographic technique based on reverse phase HPLC (rp-HPLC). This technique was used to monitor the oxidation, deamidation and formation of an unknown species of omega-interferon in the formulations. The peroxide content of the vehicle was determined using EP 2002, 2.5.5 (Method A with auto titration), See Extra Pharmacopoeia, 2002 Ed. Content and purity assay of omega-interferon by size exclusion chromatography (SEC).
Reverse Phase High Performance Liquid Chromatography
Purity assay and identity of omega-interferon recombinant in suspension systems by reverse phase high performance liquid chromatography (rp-HPLC).
The stability of omega-interferon was monitored in two different lots of untreated SAIB (as received) and in treated SAID (removal of peroxides), when treatment was applied.
The studies are outlined below:
Materials and Equipment
The following tables, Table 2 and Table 3, provide a list of materials and equipment that can be utilized to perform the experiments described, below.
The preliminary stability study of omega interferon in untreated SAIB (lot #TD1030507, peroxide value—71.4 ppm) was over 2 weeks. The results indicated that up to 8.31% of omega-interferon was oxidized in two weeks, which corresponds to an increase of 5.51% with respect to particles (2.8% oxidation at t=0). See Table 4,
Treatment of SAIB with Neutral Alumina with Heating
SAIB was heated to 75° C. Alumina (15% w/w) was added to the heated SAW. The mixture was stirred for 40 minutes and filtered though a 5.0 μm filter at 75° C. The treated SAIB was then collected, sampled for peroxide testing, and used for preparation of suspension for stability testing.
Treatment of SAIB with Neutral Alumina in Presence of Ethanol
SAIB was mixed with 15% absolute ethanol to reduce the viscosity. Basic alumina (15% w/w) was added to the SAIB containing ethanol. The resulting mixture was stirred for 1 hour and filtered though a 0.2 μm filter. The filtered SAIB was placed overnight under vacuum at 60° C. to remove the ethanol. This treated SAIB was then collected, sampled for peroxide testing, and used for preparation of suspension for stability testing.
The stability of omega-interferon in alumina treated SAIB was tested. After one month in the neutral alumina treated SAIB (Study IIa and IIb), oxidation of omega-interferon increased by about 5.7% for both IIa and IIb. This indicates that alumina treatment of SAIB did not improve the stability of omega-interferon in SAIB. See Table 5. In addition, this analysis is also reflected in the high peroxide content of alumina treated SAIB (66.3 and 62.9 ppm, respectively). Treatment with neutral alumina was not effective in decreasing peroxide content.
Stability of omega-interferon in untreated SAIB was again tested. The results of a two week stability study (Study III) of omega-interferon in SAIB (lot #TD 2032663) are comparable to studies I and II. See Table 6,
Treatment of SAIB with Basic Alumina with Heating
SAIB was heated to 90° C. Basic alumina (15% w/w) was added to the heated SAIB. Two different grades of alumina were used—Basic Super I and Basic Standard Activity I. The resulting mixture was stirred for 40 minutes. The mixture was then centrifuged at 4000 rpm while temperature was maintained at 75° C. After centrifugation, the supernatant was collected and sampled for peroxide analysis.
Treatment of SAIB with 10% Aqueous Solution of Methionine
One part of SAIB was vigorously agitated with 4 parts of 10% aqueous solution of methionine at 80° C. for 45 minutes using a magnetic stirrer. (Evaporated water was replenished as necessary) Afterwards, the methionine solution was decanted. SAIB was then washed with 4 parts of water by agitating for 15 minutes at 70°-80° C. This washing step was carried out three times. SAIB was placed overnight in vacuum oven at 70° C. to remove residual water, and, afterwards, was sampled for peroxide analysis.
The peroxide content of SAIB treated with basic alumina or with aqueous methionine solution was determined to be 1.09.3 and 95.7 respectively (Study IV and V), indicating that these approaches were not successful in the removal of peroxides. See
Treatment of SAIB with 5% Aqueous Solution of Sodium Metabisulfite in Presence of Hexane
SAIB was dissolved in two parts of hexane. The resulting solution was treated with a 5% aqueous solution of sodium metabisulfite by vigorous shaking. The aqueous layer was removed and the SAIB layer was washed with water. The SAIB layer was dried with MgSO4. Hexane was removed from SAIB by evaporation under vacuum at 50° C. The treated SAIB was sampled for peroxide analysis and used for preparation of suspension for stability testing.
The stability study (Study VIa and VIb, Table 7,
As shown in
It is to be appreciated that certain features of the invention which are, for clarity, described above in the context of separate embodiments, may also be provided in combination in a single embodiment. Conversely, various features of the invention that are, for brevity, described in the context of a single embodiment, may also be provided separately or in any subcombination. Further, reference to values stated in ranges includes each and every value within that range, unless clearly expressed otherwise.
The entire disclosure of each patent, patent application, and publication cited or described in this document is incorporated herein by reference.
This application claims the benefit of U.S. provisional application No. 60/702,546, filed Jul. 26, 2005, which is incorporated herein in its entirety.
| Number | Name | Date | Kind |
|---|---|---|---|
| 2931802 | Toney | Apr 1960 | A |
| 3215137 | Laakso et al. | Nov 1965 | A |
| 3346381 | Grieg | Oct 1967 | A |
| 3473949 | Eldred et al. | Oct 1969 | A |
| 3743398 | Johnson et al. | Jul 1973 | A |
| 3755466 | Reuter et al. | Aug 1973 | A |
| 3763018 | Raff | Oct 1973 | A |
| 3797492 | Place | Mar 1974 | A |
| 3853837 | Fujino et al. | Dec 1974 | A |
| 3962162 | Sclunank | Jun 1976 | A |
| 3987790 | Eckenhoff et al. | Oct 1976 | A |
| 3992365 | Beddell et al. | Nov 1976 | A |
| 4008719 | Theeuwes et al. | Feb 1977 | A |
| 4024248 | Konig et al. | May 1977 | A |
| 4069251 | Mannsfield et al. | Jan 1978 | A |
| 4100274 | Dutta et al. | Jul 1978 | A |
| 4304767 | Heller et al. | Dec 1981 | A |
| 4305927 | Theeuwes et al. | Dec 1981 | A |
| 4395405 | Noda et al. | Jul 1983 | A |
| 4395495 | Cununings | Jul 1983 | A |
| 4411890 | Momany | Oct 1983 | A |
| 4487603 | Harris | Dec 1984 | A |
| 4530840 | Tice et al. | Jul 1985 | A |
| 4562024 | Rogerson | Dec 1985 | A |
| 4622219 | Haynes | Nov 1986 | A |
| 4630019 | Portner et al. | Dec 1986 | A |
| 4692147 | Duggan | Sep 1987 | A |
| 4725442 | Haynes | Feb 1988 | A |
| 4725852 | Gamblin et al. | Feb 1988 | A |
| 4767628 | Hutchinson | Aug 1988 | A |
| 4782104 | Nakanishi | Nov 1988 | A |
| 4795641 | Kashdan | Jan 1989 | A |
| 4834984 | Goldie et al. | May 1989 | A |
| 4844909 | Goldie et al. | Jul 1989 | A |
| 4861598 | Oshlack | Aug 1989 | A |
| 4865845 | Eckenhoff et al. | Sep 1989 | A |
| 4874388 | Wong et al. | Oct 1989 | A |
| 4891225 | Langer | Jan 1990 | A |
| 4906474 | Langer | Mar 1990 | A |
| 4938763 | Dunn et al. | Jul 1990 | A |
| 4957744 | Della Valle et al. | Sep 1990 | A |
| 4970075 | Oshlack | Nov 1990 | A |
| 4990341 | Goldie et al. | Feb 1991 | A |
| 5034229 | Magruder et al. | Jul 1991 | A |
| 5057318 | Magruder et al. | Oct 1991 | A |
| 5059423 | Magruder et al. | Oct 1991 | A |
| 5110596 | Magruder et al. | May 1992 | A |
| 5112614 | Magruder et al. | May 1992 | A |
| 5137727 | Eckenhoff | Aug 1992 | A |
| 5149543 | Cohen | Sep 1992 | A |
| 5151093 | Theeuwes et al. | Sep 1992 | A |
| 5188837 | Domb | Feb 1993 | A |
| 5192743 | Hsu et al. | Mar 1993 | A |
| 5219572 | Sivaramakishnan et al. | Jun 1993 | A |
| 5234692 | Magruder et al. | Aug 1993 | A |
| 5234693 | Magruder et al. | Aug 1993 | A |
| 5266331 | Oshlack et al. | Nov 1993 | A |
| 5278201 | Dunn et al. | Jan 1994 | A |
| 5278202 | Dunn et al. | Jan 1994 | A |
| 5279608 | Cherif Cheikh | Jan 1994 | A |
| 5286496 | Stapler et al. | Feb 1994 | A |
| 5308348 | Balaban et al. | May 1994 | A |
| 5312389 | Theeuwes et al. | May 1994 | A |
| 5324519 | Dunn et al. | Jun 1994 | A |
| 5324520 | Dunn et al. | Jun 1994 | A |
| 5330835 | Kikuchi et al. | Jul 1994 | A |
| 5336057 | Fukuda et al. | Aug 1994 | A |
| 5340572 | Patel et al. | Aug 1994 | A |
| 5340849 | Dunn et al. | Aug 1994 | A |
| 5350741 | Takada | Sep 1994 | A |
| 5352662 | Brooks et al. | Oct 1994 | A |
| 5356635 | Raman et al. | Oct 1994 | A |
| 5368588 | Bettinger | Nov 1994 | A |
| 5370864 | Peterson et al. | Dec 1994 | A |
| 5382424 | Stapler et al. | Jan 1995 | A |
| 5391381 | Wong et al. | Feb 1995 | A |
| 5399353 | Bartnik et al. | Mar 1995 | A |
| 5399363 | Liversidge et al. | Mar 1995 | A |
| 5442033 | Bezwada | Aug 1995 | A |
| 5456679 | Balaban et al. | Oct 1995 | A |
| 5478577 | Sacklet et al. | Dec 1995 | A |
| 5487898 | Lu et al. | Jan 1996 | A |
| 5505922 | Thut | Apr 1996 | A |
| 5511355 | Dingler | Apr 1996 | A |
| 5540912 | Roorda et al. | Jul 1996 | A |
| 5545408 | Trigg et al. | Aug 1996 | A |
| 5549912 | Oshlack et al. | Aug 1996 | A |
| 5557318 | Gabriel | Sep 1996 | A |
| 5569450 | Duan et al. | Oct 1996 | A |
| 5599552 | Dunn et al. | Feb 1997 | A |
| 5599852 | Scopelianos | Feb 1997 | A |
| 5628993 | Yamagata | May 1997 | A |
| 5633000 | Grossman et al. | May 1997 | A |
| 5656295 | Oshlack et al. | Aug 1997 | A |
| 5672360 | Sackler et al. | Sep 1997 | A |
| 5702716 | Dunn et al. | Dec 1997 | A |
| 5713847 | Howard, III et al. | Feb 1998 | A |
| 5725841 | Duan et al. | Mar 1998 | A |
| 5728396 | Peery et al. | Mar 1998 | A |
| 5733950 | Dunn et al. | Mar 1998 | A |
| 5736152 | Dunn | Apr 1998 | A |
| 5739176 | Dunn et al. | Apr 1998 | A |
| 5747051 | Granger et al. | May 1998 | A |
| 5747058 | Tipton et al. | May 1998 | A |
| 5750100 | Yamagata et al. | May 1998 | A |
| 5759563 | Yewey et al. | Jun 1998 | A |
| 5777124 | Zavareh et al. | Jul 1998 | A |
| 5780044 | Yewey et al. | Jul 1998 | A |
| 5786484 | Dyer et al. | Jul 1998 | A |
| 5801012 | Soff et al. | Sep 1998 | A |
| 5836935 | Ashton et al. | Nov 1998 | A |
| 5840329 | Bai | Nov 1998 | A |
| 5874388 | Hsu | Feb 1999 | A |
| 5879705 | Heafield et al. | Mar 1999 | A |
| 5919473 | Elkhoury | Jul 1999 | A |
| 5932597 | Brown | Aug 1999 | A |
| 5942241 | Chasin et al. | Aug 1999 | A |
| 5968542 | Tipton | Oct 1999 | A |
| 5976109 | Hemth | Nov 1999 | A |
| 5985305 | Peery et al. | Nov 1999 | A |
| 5994548 | Langston et al. | Nov 1999 | A |
| 5997527 | Gumucio et al. | Dec 1999 | A |
| 5997902 | Maruyama et al. | Dec 1999 | A |
| 6008355 | Huang et al. | Dec 1999 | A |
| 6042811 | Duan et al. | Mar 2000 | A |
| 6051558 | Burns et al. | Apr 2000 | A |
| 6093420 | Baichwal | Jul 2000 | A |
| 6113938 | Chen et al. | Sep 2000 | A |
| 6126919 | Stefely et al. | Oct 2000 | A |
| 6130200 | Brodbeck et al. | Oct 2000 | A |
| 6132420 | Dionne et al. | Oct 2000 | A |
| 6143322 | Sacl<ler et al. | Nov 2000 | A |
| 6156331 | Peery et al. | Dec 2000 | A |
| 6203813 | Gooberrnan | Mar 2001 | B1 |
| 6217906 | Gumucio et al. | Apr 2001 | B1 |
| 6245351 | Nara et al. | Jun 2001 | B1 |
| 6248112 | Gambale et al. | Jun 2001 | B1 |
| 6261584 | Peery et al. | Jul 2001 | B1 |
| 6270787 | Ayer | Aug 2001 | B1 |
| 6283948 | Roorda | Sep 2001 | B1 |
| 6291013 | Gibson et al. | Sep 2001 | B1 |
| 6312717 | Molinoff et al. | Nov 2001 | B1 |
| 6375978 | Kleiner et al. | Apr 2002 | B1 |
| 6384227 | Dyer et al. | May 2002 | B2 |
| 6395292 | Peery et al. | May 2002 | B2 |
| 6403609 | Asgherian | Jun 2002 | B1 |
| 6413536 | Gibson et al. | Jul 2002 | B1 |
| 6420454 | Wenz et al. | Jul 2002 | B1 |
| 6426339 | Berde et al. | Jul 2002 | B1 |
| 6436091 | Harper et al. | Aug 2002 | B1 |
| 6440493 | Gibson et al. | Aug 2002 | B1 |
| 6447522 | Gambale et al. | Sep 2002 | B2 |
| 6468961 | Brodbeck et al. | Oct 2002 | B1 |
| 6479074 | Murdock et al. | Nov 2002 | B2 |
| 6486138 | Asgherian et al. | Nov 2002 | B1 |
| 6498153 | Cady et al. | Dec 2002 | B1 |
| 6508808 | Carr et al. | Jan 2003 | B1 |
| 6514516 | Chasin et al. | Feb 2003 | B1 |
| 6521259 | Chasin et al. | Feb 2003 | B1 |
| 6524607 | Goldenheim et al. | Feb 2003 | B1 |
| 6525102 | Chen et al. | Feb 2003 | B1 |
| 6699908 | Sackler | Mar 2004 | B2 |
| 6733783 | Oshlack | May 2004 | B2 |
| 6840931 | Peterson et al. | Jan 2005 | B2 |
| 6921541 | Chasin et al. | Jul 2005 | B2 |
| 6992065 | Okumu | Jan 2006 | B2 |
| 7053209 | Gibson et al. | May 2006 | B1 |
| 7833543 | Gibson et al. | Nov 2010 | B2 |
| 8133507 | Yum et al. | Mar 2012 | B2 |
| 8147870 | Yum et al. | Apr 2012 | B2 |
| 8153149 | Verity | Apr 2012 | B2 |
| 8153152 | Yum et al. | Apr 2012 | B2 |
| 8153661 | Verity | Apr 2012 | B2 |
| 8168217 | Yum et al. | May 2012 | B2 |
| 8231903 | Fraatz et al. | Jul 2012 | B2 |
| 8337883 | Yum et al. | Dec 2012 | B2 |
| 8354124 | Yum et al. | Jan 2013 | B2 |
| 8415401 | Yum et al. | Apr 2013 | B2 |
| 8420120 | Yum et al. | Apr 2013 | B2 |
| 8496943 | Fereira et al. | Jul 2013 | B2 |
| 8753665 | Verity | Jun 2014 | B2 |
| 8846072 | Verity | Sep 2014 | B2 |
| 8945614 | Yum et al. | Feb 2015 | B2 |
| 8951556 | Yum et al. | Feb 2015 | B2 |
| 20010000522 | Dyer et al. | Apr 2001 | A1 |
| 20010029257 | Murdock et al. | Oct 2001 | A1 |
| 20020001631 | Okumu | Jan 2002 | A1 |
| 20020064536 | Hunt | May 2002 | A1 |
| 20020114835 | Sackler et al. | Aug 2002 | A1 |
| 20020173552 | Cleland et al. | Nov 2002 | A1 |
| 20030044467 | Brodbeck et al. | Mar 2003 | A1 |
| 20030045454 | Okumu et al. | Mar 2003 | A1 |
| 20030059376 | Libbey et al. | Mar 2003 | A1 |
| 20030108609 | Berry et al. | Jun 2003 | A1 |
| 20030114430 | MacLeod et al. | Jun 2003 | A1 |
| 20030152637 | Chasin et al. | Aug 2003 | A1 |
| 20030170289 | Chen et al. | Sep 2003 | A1 |
| 20030180364 | Chen et al. | Sep 2003 | A1 |
| 20030185873 | Chasin et al. | Oct 2003 | A1 |
| 20030215515 | Truong-le et al. | Nov 2003 | A1 |
| 20040001889 | Chen et al. | Jan 2004 | A1 |
| 20040024021 | Sudo et al. | Feb 2004 | A1 |
| 20040024069 | Chen et al. | Feb 2004 | A1 |
| 20040042194 | Hsieh | Mar 2004 | A1 |
| 20040052336 | Langlet et al. | Mar 2004 | A1 |
| 20040101557 | Gibson et al. | May 2004 | A1 |
| 20040109893 | Chen et al. | Jun 2004 | A1 |
| 20040138237 | Shah | Jul 2004 | A1 |
| 20040142902 | Struijker- Boudier | Jul 2004 | A1 |
| 20040146562 | Shah | Jul 2004 | A1 |
| 20040151753 | Chen et al. | Aug 2004 | A1 |
| 20040161382 | Yum et al. | Aug 2004 | A1 |
| 20040208845 | Michal et al. | Oct 2004 | A1 |
| 20040224019 | Zale et al. | Nov 2004 | A1 |
| 20040224903 | Berry et al. | Nov 2004 | A1 |
| 20050008661 | Fereira et al. | Jan 2005 | A1 |
| 20050042194 | Ng et al. | Feb 2005 | A1 |
| 20050095284 | Trautman | May 2005 | A1 |
| 20050106214 | Chen | May 2005 | A1 |
| 20050106304 | Cook et al. | May 2005 | A1 |
| 20050171052 | Cook et al. | Aug 2005 | A1 |
| 20050232876 | Minga et al. | Oct 2005 | A1 |
| 20050244489 | Paris | Nov 2005 | A1 |
| 20050266087 | Junnarkar et al. | Dec 2005 | A1 |
| 20050276856 | Fereira et al. | Dec 2005 | A1 |
| 20050281879 | Chen et al. | Dec 2005 | A1 |
| 20060034926 | Fraatz et al. | Feb 2006 | A1 |
| 20060058401 | Ishikawa et al. | Mar 2006 | A1 |
| 20060165800 | Chen et al. | Jul 2006 | A1 |
| 20060210599 | Gibson et al. | Sep 2006 | A1 |
| 20080023261 | Kaneko et al. | Jan 2008 | A1 |
| 20080145419 | Gibson et al. | Jun 2008 | A1 |
| 20080152708 | Gibson et al. | Jun 2008 | A1 |
| 20080167630 | Verity | Jul 2008 | A1 |
| 20080206321 | Yum et al. | Aug 2008 | A1 |
| 20080287464 | Wright et al. | Nov 2008 | A1 |
| 20090023689 | Yum et al. | Jan 2009 | A1 |
| 20090023690 | Yum et al. | Jan 2009 | A1 |
| 20090036490 | Verity | Feb 2009 | A1 |
| 20090037490 | Ohira | Feb 2009 | A1 |
| 20090215808 | Yum et al. | Aug 2009 | A1 |
| 20090298862 | Yum et al. | Dec 2009 | A1 |
| 20110009451 | Verity | Jan 2011 | A1 |
| 20120135072 | Yum et al. | May 2012 | A1 |
| 20120135073 | Yum et al. | May 2012 | A1 |
| 20120177697 | Chen | Jul 2012 | A1 |
| 20130251674 | Fereira et al. | Sep 2013 | A1 |
| 20130281480 | Yum et al. | Oct 2013 | A1 |
| 20130287845 | Yum et al. | Oct 2013 | A1 |
| 20130289053 | Wright et al. | Oct 2013 | A1 |
| 20130289069 | Verity | Oct 2013 | A1 |
| 20130295168 | Yum et al. | Nov 2013 | A1 |
| 20130317049 | Yum et al. | Nov 2013 | A1 |
| 20130337059 | Yum et al. | Dec 2013 | A1 |
| 20130337060 | Yum et al. | Dec 2013 | A1 |
| 20130345260 | Gibson et al. | Dec 2013 | A1 |
| 20140275147 | Yum et al. | Sep 2014 | A1 |
| 20140308352 | Wright et al. | Oct 2014 | A1 |
| 20150196644 | Yum et al. | Jul 2015 | A1 |
| Number | Date | Country |
|---|---|---|
| 8374575 | Aug 1975 | AU |
| 2222567 | Dec 1996 | CA |
| 2283517 | Apr 1998 | CA |
| 2291087 | Dec 1998 | CA |
| 2303442 | Mar 1999 | CA |
| 1569231 | Aug 1969 | DE |
| 2213717 | Nov 1972 | DE |
| 2321174 | Nov 1973 | DE |
| 2438352 | Feb 1976 | DE |
| 2720245 | Nov 1977 | DE |
| 19520237 | Dec 1996 | DE |
| 19714765 | Oct 1998 | DE |
| 0244118 | Nov 1987 | EP |
| 0290983 | Nov 1988 | EP |
| 0413528 | Feb 1991 | EP |
| 0539751 | Oct 1991 | EP |
| 0535899 | Apr 1993 | EP |
| 0537559 | Apr 1993 | EP |
| 0539559 | May 1993 | EP |
| 0621042 | Oct 1994 | EP |
| 0635531 | Jan 1995 | EP |
| 0640336 | Mar 1995 | EP |
| 0671162 | Sep 1995 | EP |
| 0711548 | May 1996 | EP |
| 0773034 | May 1997 | EP |
| 0999825 | May 2000 | EP |
| 1010436 | Jun 2000 | EP |
| 0782569 | Mar 2002 | EP |
| 0804417 | Jun 2003 | EP |
| 0788480 | Jul 2003 | EP |
| 0788481 | Aug 2003 | EP |
| 1348427 | Oct 2003 | EP |
| 1032390 | Nov 2003 | EP |
| 0778768 | May 2004 | EP |
| 15480093 | Jun 2005 | EP |
| 1212092 | Oct 2005 | EP |
| 2238478 | Oct 2010 | EP |
| 1088992 | Oct 1967 | GB |
| 2238478 | Jun 1991 | GB |
| S59210024 | Nov 1984 | JP |
| S62000419 | Jan 1987 | JP |
| 63302858 | Dec 1988 | JP |
| 2096516 | Apr 1990 | JP |
| H05194273 | Aug 1993 | JP |
| H0753356 | Feb 1995 | JP |
| 07070297 | Mar 1995 | JP |
| H07112940 | May 1995 | JP |
| H07115901 | May 1995 | JP |
| H07124196 | May 1995 | JP |
| 8505395 | Jun 1996 | JP |
| 08206191 | Aug 1996 | JP |
| 8512303 | Dec 1996 | JP |
| H09502181 | Mar 1997 | JP |
| 2000185091 | Jul 2000 | JP |
| 4330175 | Jun 2009 | JP |
| 4501076 | Jul 2010 | JP |
| WO1990003768 | Apr 1990 | WO |
| WO1990003809 | Apr 1990 | WO |
| WO1991016929 | Nov 1991 | WO |
| WO1991017900 | Nov 1991 | WO |
| WO1991018016 | Nov 1991 | WO |
| WO1992017900 | Oct 1992 | WO |
| WO1993000006 | Jan 1993 | WO |
| WO1993003751 | Mar 1993 | WO |
| WO1993007833 | Apr 1993 | WO |
| WO1994005265 | Mar 1994 | WO |
| WO1994015587 | Jul 1994 | WO |
| WO1995001786 | Jan 1995 | WO |
| WO1995006693 | Mar 1995 | WO |
| WO1995009613 | Apr 1995 | WO |
| WO1995017901 | Jul 1995 | WO |
| WO1996009290 | Mar 1996 | WO |
| WO1996012699 | May 1996 | WO |
| WO1996012700 | May 1996 | WO |
| WO1996022281 | Jul 1996 | WO |
| WO1996039995 | Dec 1996 | WO |
| WO1996041616 | Dec 1996 | WO |
| WO1997015285 | May 1997 | WO |
| WO1997027840 | Aug 1997 | WO |
| WO1997049391 | Dec 1997 | WO |
| WO1998027962 | Jul 1998 | WO |
| WO1998027963 | Jul 1998 | WO |
| WO1998034596 | Aug 1998 | WO |
| WO1998044903 | Oct 1998 | WO |
| WO1998051246 | Nov 1998 | WO |
| WO1998053837 | Dec 1998 | WO |
| WO1999006023 | Feb 1999 | WO |
| WO1999013913 | Mar 1999 | WO |
| WO1999025349 | May 1999 | WO |
| WO1999033446 | Jul 1999 | WO |
| WO2000000120 | Jan 2000 | WO |
| WO2000000181 | Jan 2000 | WO |
| WO2000033866 | Jun 2000 | WO |
| WO2000045790 | Aug 2000 | WO |
| WO2000054745 | Sep 2000 | WO |
| WO2001 043528 | Dec 2000 | WO |
| WO2000078335 | Dec 2000 | WO |
| WO2001042518 | Dec 2000 | WO |
| WO2001015734 | Mar 2001 | WO |
| WO2001051024 | Jul 2001 | WO |
| WO2001051041 | Jul 2001 | WO |
| WO2001 076599 | Oct 2001 | WO |
| WO2001 078983 | Oct 2001 | WO |
| WO2001 049336 | Dec 2001 | WO |
| WO200201 0436 | Feb 2002 | WO |
| WO2002028366 | Apr 2002 | WO |
| WO2002043800 | Jun 2002 | WO |
| WO2002053187 | Jul 2002 | WO |
| WO2002067895 | Sep 2002 | WO |
| WO2003000282 | Jan 2003 | WO |
| WO2003041684 | May 2003 | WO |
| WO2003041757 | May 2003 | WO |
| WO2003072113 | Sep 2003 | WO |
| WO2003086368 | Oct 2003 | WO |
| WO2003101358 | Dec 2003 | WO |
| WO2003101961 | Dec 2003 | WO |
| WO2004007451 | Jan 2004 | WO |
| WO2004011032 | Feb 2004 | WO |
| WO2004037224 | May 2004 | WO |
| WO2004037289 | May 2004 | WO |
| WO2004052336 | Jun 2004 | WO |
| WO2004056338 | Jul 2004 | WO |
| WO2004082658 | Sep 2004 | WO |
| WO2004089335 | Oct 2004 | WO |
| WO2004101557 | Nov 2004 | WO |
| WO2005009408 | Feb 2005 | WO |
| WO20050487 44 | Jun 2005 | WO |
| WO2005048930 | Jun 2005 | WO |
| WO2005049069 | Jun 2005 | WO |
| WO2005105031 | Nov 2005 | WO |
| WO2005115333 | Dec 2005 | WO |
| WO2006033948 | Mar 2006 | WO |
| WO2006083950 | Aug 2006 | WO |
| WO2006084139 | Aug 2006 | WO |
| WO2006084140 | Aug 2006 | WO |
| WO2006084141 | Aug 2006 | WO |
| WO2008023261 | Feb 2008 | WO |
| WO2014144984 | Sep 2014 | WO |
| Entry |
|---|
| U.S. Appl. No. 14/464,624, filed Aug. 20, 2014, Verity. |
| “3M DDS Announces Development of New HFA-Compatible Excipients: Novel Oligomeric Acids as MDI Suspension Aids and Solubilizers,” (2000) 3M Delivery. |
| Adams EG, et al. “A comparison of the abuse liability oftramadol, NSAIDS, and hydrocodone in patients with chronic pain.” Journal of Pain and Symptom Management. 31(5), 465-4 76 2006. |
| Ahuja et al. (1995) “Intra-Articular Morphine Versus Bupivacaine for Postoperative Analgesia Following Knee Arthroscopy” The Knee 2(4):227-231. |
| Ajayaghosh, A., et al., “Solid-Phase Synthesis of N-Methyl and N-Ethylamides of Peptides Using Photolytically Detachable ((3-Nitro-4-((alkylamino)methyl)benzamido)methyl)polystrene Resin,” J. Org. Chem., 55:2826 (1990). |
| Allahham A, et al. “Flow and injection characteristics of pharmaceutical parenteral formulations using a micro-capillary rheometer”. Int J Pharm. 2004;270(1-2): 139-48. |
| Ansel, H.C. et al., Pharmaceutical Dosage Forms and Drug Delivery System, sixth ed., (1995). |
| Barb, R. et al., “Evaluation of the Saber Delivery System for the Controlled Release of Deslorelin: Effect of Dose in Estrogen Primed Ovarectomized Gilts,” Proceed. lnt'I Symp. Control. Rel. Bioact. Mater. 26 (1999). |
| Bartfield et al. (1998) “Randomized Trial of Diphenhydramine Versus Benzyl Alcohol with Epinephrine as an Alternative to Lidocaine Local Anesthesia” Ann Emerg Med 32(6):650-654. |
| Bartfield et al. (2001) “Benzyl Alcohol with Epinephrine as an Alternative to Lidocaine With Epinephrine” J Emerg Med 21(4):375-379. |
| Bartosz, et al., (1997) “Antioxidant and Prooxidant Properties of Captopril and Enalapril”,Free Radical Biology & Medicine, 23(5):729-735. |
| Becker, S.E., et al. “Effects of Gonadotropin-Releasing Hormone Infused in a Pulsatile or Continuous Fashion on Serum Gonadotropin Concentrations and Ovulation in the Mare,” J. Anim. Sci. (1992) 70:1208-1215. |
| Bekersky I, et al. “Effect oflow- and high-fat meals on tacrolimus absorption following 5 mg single oral doses to healthy human subjects.” J Clin Pharmacol 2001; 41(2): 176-82. |
| Betschart, R., et al., “Evaluation of the Saber.TM. Delivery System for the Controlled Release of the GnRH Analogue Deslorelin for Advancing Ovulation in Mares: Effect of Gamma Radiation”; Proceed. lnt'I Symp. Control. Rel. Bioact. Mater. 25 (1998) Controlled Release Society, Inc. pp. 655-656. |
| Bhatia & Singh “Percutaneous Absorption of LHRH Through Porcine Skin: Effect of N-Methyl 2-Pyrrolidone and Isopropyl Myristate”; Drug Development & Industrial Pharmacy 23(11):1113-1114 (1997). |
| Brevard J, et al. “Pain and opioid abuse in a population of substance abuse patients: data from the NA VIPPRO system”; Conference paper presented at the 42nd American Pain Society (APS) Annual Scientific Meeting, Washington, D.C. 2007. |
| Buhler, K., GnRH Agonists and Safety, in GnRH Analagoues the State of the Art 1993, a Summary of the 3rd International Symposium on GnRH Analogues in Cancer and Human Reproduction, Geneva, Feb. 1993. |
| Burns, P. et al., “Pharmacodynamic Evaluation of the Saber.TM. Delivery System for the Controlled Release of the GnRH Analogue Deslorelin Acetate for Advancing-Ovulation in Cyclic Mares,” Proceed. lnt'I. Symp. Control. Rel. Bioact. Mater., 24 (1997), Controlled Release Society, Inc. |
| Cellulose Acetate Butyrate. In: European pharmacopoeia. 4 edn. Strasbourg Cedex, France: Council of Europe; 2001; p. 853-4. |
| Coy, et al., “Solid Phase Synthesis of Lutcinizing Hormone-Releasing Hormone and Its Analogs,” Methods Enzymol. 37, 416 (1975). |
| D 2857-95 (2001) “Standard Practice for Dilute Solution Viscosity of Polymers” Copyright by ASTM lnt'l. |
| DE, Asim K. and DE, Avik, (2014), “Reaction Rate Constants for Hydrogen Peroxide Oxidation of Phenol and Chlorinated Phenols in a Continuous Stirred Tank Reactor”, International Journal of Engineering Research & Technology (IJERT), 3(6):222-226. |
| Desai et al., “Surface Modification of Polymeric Biomaterials for Reduced Thrombogenicity,” Polym. Mater. Sci. Eng., 62:731-735 (1990). |
| Dodson, K.M., et al. “Oral Controlled Release of Antiretrovirals Using the SABER Delivery System Incorporated into Soft Gelatin Capsules”, AAPS Meeting, 1999, New Orleans, LA. |
| Duan, D. et al., “Novel Dispersing Aids for Hydrofluoroalkane-Based Metered Dose Inhalers,” 1998 Conference of the American Association of Pharmaceutical Scientists, San Francisco, California, Nov. 1998. |
| Duan, D. et al., “Oligomeric Lactic Acids as Solubilizing Aids for HFA-Based Metered Dose Inhalers,” 1998 Conference of the American Association of Pharmaceutical Scientists, San Francisco, California, Nov. 1998. |
| Dunbar SA, Katz NP “Chronic opioid therapy for nonmalignant pain in patients with a history of substance abuse: report of20 cases.” Journal of Pain and Symptom Management. 11 (3), 163-1 7 1. 1996. |
| English Translation of Japanese Office Action dated Mar. 6, 2012 for Japanese Patent Application No. 2009-108881. |
| English Translation of Japanese Office Action dated Mar. 6, 2012 for Japanese Patent Application No. 2009-2735. |
| Fitzgerald, B.P, et al., “Effect of Constant Administration of a Gonadotropin-Releasing Hormone Agonist on Reproductive Activity in Mares: Preliminary Evidence on Suppression of Ovulation During the Breeding Season,” Am. J. Vet. Res., 1993, 54(10):1746-1751. |
| Fleury, J., et al., “Evaluation of the Saber.TM. Delivery System for the Controlled Release of the Deslorelin for Advancing Ovulation in the Mare: Effects of Formulation & Dose,” Proceed. lnt'I. Symp. Control. Rel. Bioact. Mater. 25 (1998) Controlled Release Society, Inc. pp. 657-658. |
| Gilderman L., et al. “RemoxyJM: a New Opioid Drug with Effective Analgesia and Abuse-Resistance.” American Pain Society Annual Meeting, San Antonio, TX, May 2006. |
| Ginther, O.J., Reproductive Biology of the Mare: Basic and Applied Aspects, EquiServices, Chapter 12, 499-508 Cross Plains, Wisconsin (1970). |
| Ginther, O.J. et al. “Effect of a Synthetic Gonadotropin-Releasing Hormone on Plasma Concentrations of Luteinizing Hormone in Ponies,” Am. J. Vet. Res., 35: 79-81 (1974). |
| Ginther, O.J., “Ultrasonic Imaging and Reproductive Events in the Mare,” Equiservices, Cross Plains, WI Chapter 4:43-72 (1986). |
| Glajchen, M. “Chronic Pain: Treatment Barriers and Strategies for Clinical Practice.” JAM Board Fam Pract. 2001, 14(3): 178-183. |
| Harrison, L., et al. “Comparison of HCG, Buserelin and Luprostiol for Induction of Ovulation in Cycling Mares,” J. Eq. Vet. Sci., 11:163-166 (1991). |
| Hatakeyama et al., “Synthesis and physical properties of polyurethanes from saccharide-based polycaprolactones.” Macromolecular Symposia, vol. 130, pp. 127-138, 1998. |
| Hays LR. “A profile of OxyContin addiction”; Journal of Addictive Diseases 23(4), 1-9. 2004. |
| Henry (1995) “Sucrose Acetate Isobutyrate Special Grade for Beverage Applications” International Food Ingredients No. 1 p. 47. |
| Hoskin PJ, et al. “The bioavailability and pharmacokinetics of morphine after intravenous, oral and buccal administration in healthy volunteers.” Br J Clin Pharmacol 1989; 27 (4):499-505. |
| Hoffmann, M.R. and Edwards, J.O., (1975) “Kinetics of the Oxidation of Sulfite by Hydrogen Peroxide in Acidic Solution”, The Journal of Physical Chemistry, 79(20):2096-2098. |
| Hyland, J.H., et al. “Infusion of Gonadotrophin-Releasing Hormone (GnRH) Induces of Ovulation and Fertile Oestrus in Mares During Seasonal Anoestrus,” J. Reprod. Fert., Suppl. 35 (1987):211-220. |
| Inciardi et al. (2007) “Mechanisms of prescription drug diversion among drug-involved club and street-based populations” Pain Medicine. 8(2), 17 1-183. |
| Irvine, C.H.G., “GnRH Clinical Application,”; In Equine Reproduction, (eds) McKinon, A.O. and Voss, J.L., Chapter 36, pp. 41-45, Lea & Febiger (1993). |
| Irvine, D.S., “Duration of Oestrus and Time of Ovulation in Mares Treated with Synthetic GnRH (Ay24,031),” J. Reprod. Fert. Supp. 23:279-283 (1975). |
| Ishida T, Oguri K, et al. “Isolation and identitication of urinary metabolites of oxycodone in rabbits.” Drug Metab Dispos 1979; 7 (3): 162-5. |
| Ishida T, Oguri K, Yoshimura H. “Determination of oxycodone metabolites in urines and feces of several mammalian species.” J Pharmacobiodyn 1982; 5 (7):52 1-5. |
| Iyakuhin (1974) “Jitsuyo lyakuhin Tenkabutsu (Practical Medical Additives)” Kagaku Kogyo-sha, Tokyo. |
| Japanese Office Action for Japanese Patent Application No. 2007-532447 dated Nov. 15, 2011. |
| Jochle, W., et al., Control of Ovulation in the Mare with Ovuplant.TM., a Short-Term Release Implant (STI) Containing the GNRH Analogue Deslorelin Acetate: J. Eq. Vet. Sci., 44:632 (1994). |
| Johnson & Verity (2002) “Applications of Continuous Site-Directed Drug Delivery” Proc West Pharmacal Soc 45:219-222. |
| Johnston LO, O'Malley PM, Bachman JG, Schulenberg, JE. “Monitoring the future. National results on adolescent drug use: overview of key findings” (NIH Publication No. 05-5726). Bethesda MD: National Institute on Drug Abuse 2004. |
| Kasraian et al. (1999) “Developing an Injectable Formula Containing an Oxygen-Sensitive. Drug: a Case Study of Danofloxacin Injectable” Pharm Dev Technol 4(4):475-480. |
| Katz NP, et al. “Behavioral monitoring and urine toxicology testing in patients receiving longterm opioid therapy.” Anesth Analg. 97(4), 1097-1102, (2003). |
| Katz NP, et al. “Challenges in the development of prescription opioid abuse-deterrent formulations.” Clin J Pain. 2007;23(8):648-60. |
| Katz NP, et al. “Development and preliminary experience with an ease of extractability rating system for prescription opioids.” Drug Development and Industrial Pharmacy. 32(6) 727-746(20). 2006. |
| Katz NP, et al. “Prescription monitoring of medical and non-medical Schedule u opioid abuse in Massachusetts: 1996-2005.” Conference paper presented at the 69th College on Problems of Drug Dependence (CPDD). Quebec Canada 2007. |
| Kim et al. (2001) “Comparing the Effect on Protein Stability of Methionine Oxidation Versus Mutagenesis: Steps Toward Engineering Oxidative Resistance in Proteins” Protein Engineerinq 14(5):343-347. |
| Kulkarni et al., “Polyactic Acid for Surgical Implants,”; Arch. Surg., 93:389 (1966). |
| Lacoste, D., et al., “Reversible inhibition of testicular androgen secretion by 3-, 5- and 6-month controlled-release microsphere formulations of the LH-RH agonist [d-Trp6, des-Gly-NH210] LH-RH ethylamide in the dog”; J. Steroid Biochem. 33:5, 1007-1011 (1989). |
| Lalovic B, et al. “Pharmacokinetics and pharmacodynamics of oral oxycodone in healthy human subjects: role of circulating active metabolites” Clin Pharmacol Ther 2006; 79(5):461-79. |
| Lapenna, Domenico, et al., (1995) “The Prooxidant Properties of Captopril”, Biochemical Pharmacology, 50(1):27-32. |
| Li, Shihong, et al., (1993) “Chemical Pathways of Peptide Degradation. V. Ascorbic Acid Promotes Rather than Inhibits the Oxidation of Methionine to Methionine Sulf oxide in Small Model Peptides”, Pharmaceutical Research, 10(11):1572-1579. |
| Loy, R.G. et al. “The Effects of Human Chorionic Gonadotrophin on Ovulation, Length of Estrus, and Fertility in the Mare,” Cornell Vet. 56:41-50 (1966). |
| Lu, Jian-Ming, et al., (2010) “Chemical and molecular mechanisms of antioxidants: experimental approaches and model systems”, J. Cell. Mol. Med., 14(4):840-860. |
| Material Safety Data Sheet of Eastman Chemical Products, “SAIB” Sucrose Acetate lsobutyrate, pp. 2-18. |
| Material Safety Data Sheet of Eastman Chemical Products, “SAIB” Sucrose Acetate lsobutyrate, Publication GN-311 F (Jun. 2004). |
| Material Safety Data Sheet of Eastman Fine Chemicals, “Sucrose Acetate lsobutyrate, Special Grade (SAIB-SG),” Publication No. EFC-211, May 1991. |
| Material Safety Data Sheet of Eastman Products for the Food Industry, “Sucrose Acetate lsbutyrate (SAIB-SB) for Use in Fruit-Flavored Beverages,” Publication No. ZM-90, pp. 2-7 (Sep. 1989). |
| McCabe et al. “Motives, diversion and routes of administration associated with nonmedical use of prescription opioids.” Addictive Behaviors. 32, 562-575. 2007. |
| McLellan AT, Luborsky L, Woody GE, O'Brien CP. “An improved diagnostic instrument for substance abuse patients.” The Addiction Severity Index. J Nerv Ment Dis. 1980; 168:26-33. |
| Mearns, “Changing Seasons,” The Blood-Horse, Sep. 28, 1996, 4794-4795. |
| McCarthy, P. et al., “Management of Stallions on Large Breeding Farms,” Stallion Management, vol. 8, No. 1, Apr. 1992, pp. 219-235. |
| McKinnon, A.O., et al. “Effect of a GnRH Analogue (Ovuplant), hCG and Dexamethasone on Time to Ovulation in Cycling Mares.” World Equine Veterinary Review, (1997) 2:3 16-18. |
| McKinnon, A.O., et al. “Repeated Use of a GnRH Analogue Deslorelin (Ovuplant) for Hastening Ovulation in the Transitional Mare,” Equine Vet. J., (1996) 29:2 153-155. |
| Merrifield, B., “Solid phase synthesis”; Science 232:342 (1986). |
| Meyer RJ, et al. Awareness topic: mitigating the risk of ethanol induced dose dumping from oral sustained controlled release dosage forms. In: FDA's Advisory Committee for Pharmaceutical Science Meeting, Oct. 2005. |
| Montovan, S.M., et al., “The Effect of a Potent GnRH Agonist on Gonadal and Sexual Activity in the Horse,” Theriogenology, 33:6, 1305-1321 (1990). |
| Mumford, E.L. et al., “Use of Deslorelin Short-Term Implants to Induce Ovulation in Cycling Mares During Three Consecutive Estrov Cycles,” Animal Reproduction Science, 139 (1995) 129-140. |
| Murray S, et al. “Alcohol-associated rapid release of a long-acting opioid” CMAJ 2005; 173(7):756. |
| Nakagaki (1968) “Seizai Butsuri Kagaku (Physical Chemistry of Medical Preparations),” Asakura Shoten, Tokyo. |
| Nally, J., et al., “Induction of Mucosal lgA Specific for SeMF3 for Streptococcus equi with Intranasal Vaccination Using a Sucrose Acetate lsobutyrate Based Delivery System”, Proceed. lnt'I. Symp. Control. Rel. Bioact. Mater. 26 (1999) Controlled Release Society, Inc. |
| Nett et al., “Further Studies on the Radioimmunoassay of Gonadotropin-Releasing Hormone: Effect of Radioiodination, Antiserum and Unextracted Serum on Levels of lmmunoreactivity in Serum,” Endocrinology 101:1135 (1977). |
| “New Drugs/Programs”, Current Drug Discovery, Nov. 2004 pp. 7-10. |
| “Polycaprolactone” https://en.wikipedia.org/wiki/Polycaprolactone 1 page, Jun. 16, 2008. |
| “Polyglycolide” https://en.wikipedia.org/wiki/Polyglycolide 3 pages, printed Jun. 16, 2008. |
| “Polylactic Acid”; https://en.wikipedia.org/wiki/Polylactic_acid, 1 page, printed Jun. 16, 2008. |
| Pulido et al., “Enzymatic Regioselective Acylation of Hexoses and Pentoses Using Oxime Esters.”, J. Chem. Soc. Perkin Trans. 1, (21), 2891-2898, 1992. |
| Rabb et al., “Effects of Active lmmunication Against GnRH on LH, FSH and Prolactin Storage, Sectretion and Response to Their Secretagogues in Pony Geldings,” J. Anim. Sci., 68:3322-3329 (1990). |
| Reynolds, R.C. et al., “Sucrose acetate isobutyrate (SAIB): historical aspects of its use in beverages and a review of toxicity studies prior to 1988,” Food Chem. Toxicol., 1998,36 (2), pp. 81-93. |
| Reynolds, R.C., “Metabolism and pharmacokinetics of sucrose acetate isobutyrate (SAIB) and sucrose octaisobutyrate (SOIB) in rats, dogs, monkeys or humans. a review,” Food Chern. Toxicol. 1998 36 (2). 95-99. |
| Roser, J.J., et al., “The Development of Antibodies to Human Chorionic Gonadotrpins Following its Repeated Injection in the Cyclic Mare,” J. Reprod. Fert. Suppl., 173-179 (1979). |
| Sullivan, J., “Duration of Estrus and Ovulation Time in Nonlactating Mares Given Human Chorionic Gonadotropin During Three Successive Estrous Periods,” J. Am. Vet. Med. Assoc., 63:895 (1973). |
| Sullivan, S. A., 1998, “Sustained Release of Orally Administered Active Using SABER™ Delivery System Incorporated into Soft Gelatin Capsules” Proceed. lnt'I Symp. Control. Rel. Bioact. Mater., 25:918-919. |
| Swiderski et al., “Application of 14C Isotope in Studies of Liability of Sugar Substitutents”, Nukleonike, Supl., (1996), 10, 347-52. |
| Thompson, Jr., D.L., et al., “Effects of Melatonin and Thyrotropin Releasing Hormone of Mares Durign the Nonbreeding Season,” J. Anim Sci., 58:3, 668-677(1983). |
| Thompson, Jr., D.L., et al., “Testosterone Effects on Mares During Synchoronization with Altrenogest: FSH, LH, Estrous, Duration and Pregnancy Rate,” J. Anim Sci., 56:3, 678-686 (1983). |
| Trescot AM, et al. “Opioid Guidelines in the Management of Chronic Non-Cancer Pain.” Pain Physician. 2006;9: 1-40. |
| Troen et al. (2003) “The Atherogenic Effect of Excess Methionine Intake” PNAS 100(5):15089-15094. |
| University of Utah, Department of Chemical Engineering (2006) “A Viscosity: Viscosity Definitions” http://www.che.utah.edu/department_equipment/Projects_lab/A_Viscometers/ViscosityD efinitions.pdf. |
| Vega-Rios A, Villalobos H, Mata-Segreda JF. “Acid-catalyzed hydrolysis oftriacylglycerols obeys monoexponential kinetics.” Int J Chern Kinet. 1992; 24:887-94. |
| Voss, J.L. et al. “The Effect of HCG on Duration of Oestrus, Ovulation Time and Fertility in Mares,” J. Reprod. Fert., Suppl. 23 (1975) 297-301. |
| Wilson et al. (1999) “Benzyl Alcohol as an Alternative Local Anesthetic” Ann Emerg Med 33(5):495-499. |
| Lapenna et al., (1995) “The Prooxidant Properties of Captopril,” Biochemical Pharmacology, 50(1):27-32. |
| Li et al., (1993) “Chemical Pathways of Peptide Degradation. V. Ascorbic Acid Promotes Rather than Inhibits the Oxidation of Methionine to Methionine Sulfoxide in Small Model Peptides,” Pharmaceutical Research, 10(11)1572-1579. |
| Sakagami and Satoh, (1997) “Prooxidant action of two antioxidants: ascorbic acid and gallic acid”, Anticancer Res., 17:221-224. |
| Tafazoli et al., (2005) “Prooxidant and Antioxidant Activity of Vitamin E Analogues and Troglitazone,” Chem. Res. Toxicol., 18:1567-1574. |
| Baker, M., et al., “Sulfite supported lipid peroxidation in propofol emulsions,” Anesthesiology 2002; 97: 1162-7. |
| Brannan, Robert G., “Reactive sulfur species act as prooxidants in liposomal and skeletal muscle model systems,” J. Agric. Food Chem., 2010, 58, 3767-3771. |
| Cornelli, U., et al., “Bioavailability and antioxidant activity of some food supplements in men and women using the D-Roms test as a marker of oxidative stress,” J. Nutr., 131, 3208-3211, 2011. |
| Elmas, O., et al., “The prooxidant effect of sodium metabisulfite in rat liver and kidney,” Reg. Tox. Pharm., 42: 77-82, 2005. |
| Laggner, H., et al., “Sulfite facilitates LDL lipid oxidation by transition metal ions: a pro-oxidant in wine?” FEBS Letters, 579 (2005) 6486-6492. |
| Number | Date | Country | |
|---|---|---|---|
| 20190365900 A1 | Dec 2019 | US |
| Number | Date | Country | |
|---|---|---|---|
| 60702546 | Jul 2005 | US |
| Number | Date | Country | |
|---|---|---|---|
| Parent | 15250822 | Aug 2016 | US |
| Child | 16542230 | US | |
| Parent | 13301727 | Nov 2011 | US |
| Child | 15250822 | US | |
| Parent | 11492153 | Jul 2006 | US |
| Child | 13301727 | US |
